Trade RNA anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Atrium Therapeutics, Inc. (RNA) is trading at US$13.57, down 2.97% today as of Aug 28, 13:08 EDT. The company has a market capitalisation of US$225.79M. Over the past 52 weeks, RNA has traded between US$11.13 and US$73.06. On Syfe you can trade RNA with $0 commission and add it to your watchlist.
| Previous close | US$13.98 |
|---|---|
| Market cap | US$225.79M |
| 52-week range | US$11.13 – US$73.06 |
| Volume | 119.52K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.
Year: 2026
Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome
Jul 14, 11:18 AM · MT Newswires
--Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT
May 15, 11:41 AM · MT Newswires
Atrium Therapeutics Earns $15 Million Milestone From Bristol Myers Squibb
Apr 23, 1:10 PM · MT Newswires
Atrium Therapeutics, Inc. (RNA) stock is trading at US$13.57, -2.97% from the previous close of US$13.98.
The market cap for Atrium Therapeutics, Inc. (RNA) stock is approximately US$225.79M.
The 52-week high for Atrium Therapeutics, Inc. (RNA) stock is US$73.06.
The 52-week low for Atrium Therapeutics, Inc. (RNA) stock is US$11.13.
Atrium Therapeutics, Inc. (RNA) does not currently pay a dividend.
Stay on top of RNA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
